Erratum: Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life (Clinical Therapeutics, Volume 18, Number 3, 1996, page 508-518)

M. A. Crucitt; W. Hyman; T. Grote; W. Tester; S. Madajewicz; S. Yee; A. Wentz; D. Griffin; T. V. Parasuraman; J. Bryson

doi:10.1016/S0149-2918(96)80226-8

Erratum: Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life (Clinical Therapeutics, Volume 18, Number 3, 1996, page 508-518)

M. A. Crucitt, W. Hyman, T. Grote, W. Tester, S. Madajewicz, S. Yee, A. Wentz, D. Griffin, T. V. Parasuraman, J. Bryson

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	778-788
Number of pages	11
Journal	Clinical Therapeutics
Volume	18
Issue number	4
DOIs	https://doi.org/10.1016/S0149-2918(96)80226-8
State	Published - 1996
Externally published	Yes

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1016/S0149-2918(96)80226-8

Cite this

Crucitt, M. A., Hyman, W., Grote, T., Tester, W., Madajewicz, S., Yee, S., Wentz, A., Griffin, D., Parasuraman, T. V., & Bryson, J. (1996). Erratum: Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life (Clinical Therapeutics, Volume 18, Number 3, 1996, page 508-518). Clinical Therapeutics, 18(4), 778-788. https://doi.org/10.1016/S0149-2918(96)80226-8

Erratum: Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life (Clinical Therapeutics, Volume 18, Number 3, 1996, page 508-518). / Crucitt, M. A.; Hyman, W.; Grote, T. et al.
In: Clinical Therapeutics, Vol. 18, No. 4, 1996, p. 778-788.

Research output: Contribution to journal › Article › peer-review

Crucitt, MA, Hyman, W, Grote, T, Tester, W, Madajewicz, S, Yee, S, Wentz, A, Griffin, D, Parasuraman, TV & Bryson, J 1996, 'Erratum: Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life (Clinical Therapeutics, Volume 18, Number 3, 1996, page 508-518)', Clinical Therapeutics, vol. 18, no. 4, pp. 778-788. https://doi.org/10.1016/S0149-2918(96)80226-8

Crucitt MA, Hyman W, Grote T, Tester W, Madajewicz S, Yee S et al. Erratum: Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life (Clinical Therapeutics, Volume 18, Number 3, 1996, page 508-518). Clinical Therapeutics. 1996;18(4):778-788. doi: 10.1016/S0149-2918(96)80226-8

Crucitt, M. A. ; Hyman, W. ; Grote, T. et al. / Erratum : Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life (Clinical Therapeutics, Volume 18, Number 3, 1996, page 508-518). In: Clinical Therapeutics. 1996 ; Vol. 18, No. 4. pp. 778-788.

@article{ad1853f16f8449488c1d4f9511fd516d,

title = "Erratum: Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life (Clinical Therapeutics, Volume 18, Number 3, 1996, page 508-518)",

author = "Crucitt, {M. A.} and W. Hyman and T. Grote and W. Tester and S. Madajewicz and S. Yee and A. Wentz and D. Griffin and Parasuraman, {T. V.} and J. Bryson",

note = "Funding Information: This research was supported by a grant from Glaxo Research Institute, Research Triangle Park, North Carolina. The authors wish to acknowledge the contributions of Alice Batenhorst, PharmD, and Patti Rouse, RPh, both of Glaxo Research Institute.",

year = "1996",

doi = "10.1016/S0149-2918(96)80226-8",

language = "English (US)",

volume = "18",

pages = "778--788",

journal = "Clinical Therapeutics",

issn = "0149-2918",

publisher = "Excerpta Medica",

number = "4",

}

TY - JOUR

T1 - Erratum

T2 - Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life (Clinical Therapeutics, Volume 18, Number 3, 1996, page 508-518)

AU - Crucitt, M. A.

AU - Hyman, W.

AU - Grote, T.

AU - Tester, W.

AU - Madajewicz, S.

AU - Yee, S.

AU - Wentz, A.

AU - Griffin, D.

AU - Parasuraman, T. V.

AU - Bryson, J.

N1 - Funding Information: This research was supported by a grant from Glaxo Research Institute, Research Triangle Park, North Carolina. The authors wish to acknowledge the contributions of Alice Batenhorst, PharmD, and Patti Rouse, RPh, both of Glaxo Research Institute.

PY - 1996

Y1 - 1996

UR - http://www.scopus.com/inward/record.url?scp=0029770096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029770096&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(96)80226-8

DO - 10.1016/S0149-2918(96)80226-8

M3 - Article

C2 - 8879903

AN - SCOPUS:0029770096

SN - 0149-2918

VL - 18

SP - 778

EP - 788

JO - Clinical Therapeutics

JF - Clinical Therapeutics

IS - 4

ER -

Erratum: Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life (Clinical Therapeutics, Volume 18, Number 3, 1996, page 508-518)

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this